Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC–ESMO was presented. The review considered new studies published since the second consensus conference (April 2004).
An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English.
Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists.
In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.
- Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Supportive Care in Cancer
Volume 19, Issue 1 Supplement, pp 57-62
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Moderately emetogenic chemotherapy
- Delayed emesis
- Neurokinin antagonists
- Serotonin antagonists
- Dopamine receptor antagonists
- Industry Sectors
- Author Affiliations
- 1. S. Maria Hospital, Terni, Italy
- 2. Princess Margaret Hospital, University of Toronto, Toronto, Canada
- 3. Clinique de Genolier, Genolier, Switzerland
- 4. University of Kansas Cancer Center, Kansas City, KS, USA
- 5. Walther Cancer Institute, Indianapolis, IN, USA
- 6. New York Lung Cancer Alliance, New York, NY, USA
- 7. Odense University Hospital, Odense, Denmark
- 8. Department of Breast Oncology, Juntendo University Hospital, Hongo 3-1-3, Bunkyo-ky, Tokyo, Japan, 113-8431
- 9. Regional Cancer Centre, Perugia, Italy